A Rapidly Emerging Class of Anti-Cancer Biotherapeutics
May 2-3, 2013
Antibody-drug conjugates in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. This year’s third annual Antibody-Drug Conjugates, part of the PEGS Summit, will continue to highlight updates from the clinic, as well as progress in the development of the next generation of ADCs. Novel payloads, linkers and targets will be discussed, as well as lessons learned and best practices in conjugation chemistry, conjugation site selection, linker stability, and drug/antibody ratios.
Day 1 | Day 2 | Download Brochure
THURSDAY, MAY 2
12:30 pm Conference Registration
1:30 Chairperson’s Remarks
Peter Park, Ph.D., Vice President, Biology, Mersana Therapeutics, Inc.
1:40 Early Clinical Development of ADCs at Seattle Genetics
Nancy Whiting, Pharm.D., Senior Medical Director, Seattle Genetics
In addition to a broad clinical development program with Seattle Genetics’ approved ADC ADCETRIS (brentuximab vedotin), the company has multiple other ADC programs in its pipeline. This talk will highlight novel targets and ADCs in development with a focus on the unique challenges of clinical development of ADCs.
2:10 Development of AGS15E, a Novel Antibody Drug Conjugate Targeting SLITRK6 for the Treatment of Bladder Cancer
Kendall Morrison, Ph.D., Director, Protein Technologies, Agensys, Inc. (an affiliate of Astellas Pharma)
Agensys has generated a novel antibody drug conjugate, targeting SLITRK6, which is being developed for the treatment of advanced bladder cancer. This Monomethyl Auristatin E based ADC binds to cell surface SLITRK6 with high affinity and cross reacts with the cynomolgus monkey orthologue. Selection and development of this ADC will be discussed including antibody choice, drug platform choice, assay development and other aspects of pre-clinical evaluation.
2:40 Application of Gyrolab for Efficient Bioanalysis in Antibody-Drug Conjugate (ADC) Programs
Tracey Clark, Ph.D., Senior Scientist, Drug Metabolism, PDM Biotherapeutics, PGRD Pfizer
Antibody-drug conjugates (ADC) are complex, heterogeneous mixtures of antibody with varying drug-to-antibody ratios (DAR) as cytotoxins are conjugated to different locations on the antibody. DAR can also change over time in vivo which makes bioanalysis challenging in understanding what is measured by various assay format combinations. Gyrolab is a higher throughput, nanoliter-scale immunoassay platform that enables rapid turnaround of data in drug development. In addition, assay formats can quickly be assessed while using less reagent than traditional ELISA.
3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Innovations in the Antibody-Drug Conjugate Program at Pfizer Oncology Research
Puja Sapra, Ph.D., Director, Bioconjugates Group, Oncology Research Unit, Pfizer, Inc.
Antibody-drug conjugates (ADCs) represent a promising therapeutic modality for the clinical management of cancer. This presentation will cover research activities at Pfizer focused on development of novel payloads, conjugation chemistries and target identification for development of ADCs. In addition, update on clinical data of anti-CD22 calicheamicin conjugate and preclinical data of novel ADC therapeutics will be provided.
4:30 PSMA ADC: An Antibody-Drug Conjugate in Phase 2 Clinical Trial in Prostate Cancer
William C. Olson, Ph.D., Senior Vice President, Research & Development, Progenics Pharmaceuticals, Inc.
PSMA ADC is a vcMMAE-containing antibody-drug conjugate that targets prostate-specific membrane antigen, a validated cell-surface marker of prostate cancer. Durable antitumor effects were observed in preclinical models and phase 1 clinical testing in prostate cancer patients, supporting initiation of phase 2 testing.
5:00 End of Day
Day 1 | Day 2 | Download Brochure